Adrenocortical Carcinoma

Preclinical data support future clinical development of ADCs targeting Claudin-6 and NaPi2b Additional presentations include clinical and independent preclinical studies evaluating ADCT-601 targeting AXL LAUSANNE, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced abstracts on its novel antibody drug conjugates (ADCs) have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting, which will be held in San Diego, CA from April 5-10, 2024. “We’re excited to share compelling preclinical data supporting the future clinical development of the next-generation ADCs in our solid tumor portfolio, including those targeting Claudin-6 and NaPi2b, at the AACR Annual Meeting,” said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics. “We’re also looking forward to research from independent studies that highlight the potential of another investigational ADC, ADCT-601 targeting AXL.” Details of ADC Therapeutics’ poster presentations are as follows: Title: Preclinical development of a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing Claudin-6 Abstract: 3122Session Title: Antibody-Drug ConjugatesDate and Time: Monday, April 8, 2024; 1:30 p.m. – 5:00 p.m. PTLocation: Poster Section 21; Board number 3 Title: Preclinical development of NaPi2b-PL2202, a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing NaPi2b Abstract: 5085Session Title: Novel Immunotherapies and Immune ModulationDate and Time: Tuesday, April 9, 2024; 9:00 a.m. – 12:30 p.m. PTLocation: Poster Section 42; Board number 7 Title: Phase 1b Trial Mipasetamab Uzoptirine (ADCT-601-102) dose escalation in patients with advanced bone and soft tissue sarcomasAbstract: CT059Session Title: Phase I Clinical Trials 1Date and Time: Monday, April 8, 2024; 9:00 a.m. – 12:30 p.m. PTLocation: Poster Section 48; Board number 9 Title: Quantitative systems pharmacology modeling of loncastuximab tesirine combined with mosunetuzumab and glofitamab helps guide dosing for patients with DLBCLAbstract: 875Session Title: Application of Bioinformatics to Cancer Biology 1Date and Time: Sunday, April 7, 2024; 1:30 p.m. – 5:00 p.m. PTLocation: Poster Section 36; Board number 19 Details of an independent poster presentation of an ADCT-601 preclinical study are as follows: Title: Preclinical anti-tumorigenic evaluation of AXL targeting antibody-drug-conjugate in an adenoid cystic carcinoma cell line xenograft modelAbstract: LB022Session Title: Late-Breaking Research: ChemistryDate and Time: Sunday, April 7, 2024; 1:30 p.m. – 5:00 p.m. PTLocation: Poster Section 52; Board number 4 Details of an oral presentation of an NCI-led ADCT-701 study are as follows: Title: Targeting DLK1, a Notch ligand, with an antibody-drug conjugate in adrenocortical carcinomaAbstract: 6573Session Type: MinisymposiumSession Title: Molecular, Preclinical, and Clinical Endocrinology 3Date and Time: Tuesday, April 9, 2024; 3:05 p.m. – 3:20 p.m. PTLocation: TBA About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development. ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on LinkedIn. ZYNLONTA® is a registered trademark of ADC Therapeutics SA. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “would”, “expect”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “seem”, “seek”, “future”, “continue”, or “appear” or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: future success and results from the various ADCT development programs presented at AACR, the actual ZYNLONTA® revenue for 4Q 2023, the success of the Company’s updated corporate strategy including operating efficiencies, capital deployment and portfolio prioritization; the Company’s ability to achieve the decrease in total operating expenses for 2023 and 2024, the expected cash runway into 4Q 2025, the effectiveness of the new commercial go-to-market strategy, competition from new technologies, and the Company’s ability to grow ZYNLONTA® revenue in the United States; Swedish Orphan Biovitrum AB (Sobi®) ability to successfully commercialize ZYNLONTA® in the European Economic Area and market acceptance, adequate reimbursement coverage, and future revenue from the same; approval by the NMPA of the BLA for ZYNLONTA® in China submitted by Overland ADCT BioPharma and future revenue from the same, our strategic partners’, including Mitsubishi Tanabe Pharma Corporation, ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions, and the timing and amount of future revenue and payments to us from such partnerships; the impact, if any, from data reported by the University of Miami for their IIT in FL; the timing and results of the Company’s or its partners’ clinical trials including LOTIS 5 and 7, ADCT 601 and 602 as well as the Company’s early-stage pipeline research projects, actions by the FDA or foreign regulatory authorities with respect to the Company’s products or product candidates; projected revenue and expenses; the Company’s indebtedness, including Healthcare Royalty Management and Oaktree and Blue Owl facilities, and the restrictions imposed on the Company’s activities by such indebtedness, the ability to repay such indebtedness and the significant cash required to service such indebtedness; and the Company’s ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the “Risk Factors” section of the Company's Annual Report on Form 20-F and in the Company's other periodic reports and filings with the Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. The Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law. CONTACTS: Investors and MediaNicole RileyADC TherapeuticsNicole.Riley@adctherapeutics.com+1 862-926-9040

SAN DIEGO--( BUSINESS WIRE )-- Radionetics Oncology, Inc. , a clinical stage radiopharmaceutical company focused on the discovery and development of novel agents for the treatment of a wide range of oncology indications, announces the completion of a $52.5 million Series A financing. The round was led by Frazier Life Sciences , 5AM Ventures , and new investor, DCVC Bio , with participation from Crinetics Pharmaceuticals , and GordonMD Global Investments , bringing the total raised to date to $82.5 million. Radionetics plans to use the proceeds to advance its pipeline of potent, small molecule radiopharmaceuticals targeting novel G-protein coupled receptors (GPCRs) for the treatment of a broad range of cancers. “Powered by a team with a unique expertise in radiopharmaceuticals, GPCR biology, and small molecule chemistry, Radionetics is well-positioned to be a leader in the development of first-in-class radiopharmaceuticals,” said Eric Shiozaki, Ph.D. , Partner at DCVC Bio and newly appointed Director of Radionetics Oncology. “We are excited to support Radionetics in their pursuit of developing novel and potentially life-changing radiopharmaceuticals for cancer patients.” Concurrent with the financing, Radionetics Oncology also announced the appointment of Paul Grayson as the company’s Chief Executive Officer. Paul brings a wealth of knowledge across a broad range of technologies from his time leading cutting-edge biotech companies over the past 25 years. He was most recently the President and CEO of Tentarix Biotherapeutics, an oncology company focused on multi-functional biologics. His previous experiences additionally include founding roles at Fate Therapeutics (NASDAQ: FATE), BirdRock Bio (acquired by Skye Biosciences), Senomyx (acquired by Firmenich), and Aurora Biosciences (acquired by Vertex Pharmaceuticals). “I’m thrilled to join Radionetics at such an exciting time in the evolution of the company and radiopharmaceutical therapeutics,” said Paul Grayson, President and Chief Executive Officer. “The spatial biology and pharmacology of GPCRs makes them ideal for small molecule radiopharmaceutical development, opening a new chapter for the field.” About Radionetics Oncology Radionetics Oncology, Inc. is a clinical stage radiopharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications and is poised to capitalize on the increasing demand for novel radiotherapeutics. Radionetics Oncology spun out of Crinetics Pharmaceuticals (Nasdaq: CRNX) and is supported by Frazier Life Sciences, 5AM Ventures, DCVC Bio, Crinetics Pharmaceuticals, and GordonMD Global Investments. Radionetics is advancing a pipeline of novel small molecule radioligands targeting G-protein coupled receptors for the treatment of a broad range of cancers, including adrenocortical carcinoma, breast cancer, lung cancer, among others.

Bergen, Norway, December 20, 2023 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumour membrane immunotherapy CyPep-1, today announced the election of Ellen Lubman, MBA, to its Board of Directors. “We are excited to welcome Ellen, who brings extensive experience and a well-proven track record across business development, finance, and fundraising in biopharma, to Cytovation’s Board,” said Stein Christian Mohn, Chairman of Cytovation. “Her insights and expertise will be invaluable as we continue to build our business based on advancing the development of CyPep-1 as an important new treatment for cancer patients.” “The team at Cytovation is deeply committed to bringing a potentially important new treatment option to a significant number of patients with cancer through a truly differentiated approach targeting aberrant Wnt/β-catenin signalling,” said Ellen Lubman. “I look forward to working closely with the Board and management team to help the Company achieve its mission to deliver this novel therapy for a wide range of cancer types, starting with Adrenocortical Carcinoma and expanding into other beta-catenin-driven indications, including Liver and Colorectal Cancer.” Prior to joining Werewolf Therapeutics as Chief Business Officer and Head of Investor Relations and Corporate Communications in August 2020, Ms. Lubman served as the Chief Business Officer at Impel NeuroPharma, Inc., a publicly traded biotechnology company focused on neurological diseases, from October 2018 to July 2020. Prior to Impel, she was the Vice President of External Science & Innovation at Forest Labs, from February 2014 until its acquisition by Actavis plc in July 2014, and served in the same role at Actavis through June 2018 during which time Actavis merged with and renamed itself Allergan plc. Prior to Allergan, Ms. Lubman held numerous executive and leadership roles at Kadmon Pharmaceuticals, Bristol Myers Squibb, Celtic Pharma Management, L.P., Robertson Stephens Investment Bank and Abbott Labs. Ms. Lubman has also served on the Board of Directors of Reunion Neuroscience, Inc., a privately held biotechnology company, since June 2021. She also serves as an Advisor to GeneCentric Therapeutics, Inc. where she recently held a role on the Board of Directors, and TMRW.org. Ms. Lubman’s other affiliations include Daedalus Innovation Fund of Weill-Cornell, the Red Door Community, a cancer non-for-profit previously known as Gilda’s Club of NYC, and Executive Women in BIO. Ms. Lubman earned her MBA from Stanford Graduate School of Business with a focus on Global Management, holds a Certificate in Pharmacology from the University of Medicine and Dentistry of New Jersey and a B.A. in Biology from Rutgers College. About Cytovation Cytovation ASA is a clinical stage immune-oncology company focused on the development of CyPep-1, a first-in-class immunotherapy. CyPep-1 has a unique mechanism of action, specifically eliminating cancer cells by targeting the plasma membrane, releasing neo-antigens, and inhibiting the WNT/β-catenin pathway. This dual mode of action promotes an inflammatory microenvironment and induces a tumor-specific immune response by in situ vaccination. The Company is a spin-off from the University of Bergen (Norway), the city where it is headquartered. For more information, please visit . Contact Information Cytovation Federico Grego, Chief Operating Officer/Chief Financial Officer: contact@cytovation.com MEDiSTRAVA Consulting Frazer Hall / Mark Swallow: cytovation@medistrava.com